The FDA approved Bayer and Orion’s Nubeqa (darolutamide) for men experiencing an advanced stage non-metastatic castration-resistant prostate cancer (nmCRPC). The Problem An estimated 174,650 new cases of prostate cancer are diagnosed annually and nearly 32,000 men...